TY  - JOUR
A1  - Kirsten, Natalia
A1  - Ohm, Frenz
A1  - Gehrdau, Kathrin
A1  - Girbig, Gefion
A1  - Stephan, Brigitte
A1  - Ben-Anaya, Nesrine
A1  - Pinter, Andreas
A1  - Bechara, Falk G.
A1  - Presser, Dagmar
A1  - Zouboulis, Christos C.
A1  - Augustin, Matthias
T1  - Switching from adalimumab originator to biosimilar in patients with hidradenitis suppurativa results in losses of response — data from the German HS registry HSBest
JF  - Life
N2  - Since 2021, adalimumab biosimilar ABP 501 can be used alternatively to adalimumab originator (ADAO) in the treatment of hidradenitis suppurativa (HS). Effectiveness and safety data remain scarce. We investigated the impact of switching from ADAO to ABP 501 on disease severity and the occurrence of adverse events (AEs) in patients with HS. We analyzed clinical data on patients enrolled in the German HSBest registry. Evaluation outcomes were assessed at three time points (baseline of originator (t0), prior to switching to biosimilar (t1) and 12 to 14 weeks after switching (t2)) and included patient-reported AEs and disease severity using the International Hidradenitis Suppurativa Severity Score System (IHS4) score. In total, 94 patients were switched from ADAO to ABP 501. Overall, 33.3% (n = 31/94) of the patients developed AEs and/or loss of response (LoR) within 12 to 14 weeks after switching. Of these, 61.3% (n = 19/31) experienced LoR but no AEs, 22.6% (n = 7/31) LoR combined with AEs and 16.1% (n = 5/31) AEs only. Our study showed that switching HS patients from ADAO to ABP 501 does significantly affect treatment effectiveness. Switching patients who are on remission maintenance therapy should be viewed critically.
KW  - hidradenitis suppurativa
KW  - biologics
KW  - TNF alpha
KW  - adverse drug reaction
KW  - biosimilar
KW  - drug effectiveness
KW  - switching
KW  - adalimumab
KW  - registry
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-288213
SN  - 2075-1729
VL  - 12
IS  - 10
ER  - 
TY  - JOUR
A1  - Steinke, Sabine I. B.
A1  - Peitsch, Wiebke K.
A1  - Ludwig, Alexander
A1  - Goebeler, Matthias
T1  - Cost-of-Illness in Psoriasis: Comparing Inpatient and Outpatient Therapy
JF  - PLOS ONE
N2  - Treatment modalities of chronic plaque psoriasis have dramatically changed over the past ten years with a still continuing shift from inpatient to outpatient treatment. This development is mainly caused by outpatient availability of highly efficient and relatively well-tolerated systemic treatments, in particular BioLogicals. In addition, inpatient treatment is time-and cost-intense, conflicting with the actual burst of health expenses and with patient preferences. Nevertheless, inpatient treatment with dithranol and UV light still is a major mainstay of psoriasis treatment in Germany. The current study aims at comparing the total costs of inpatient treatment and outpatient follow-up to mere outpatient therapy with different modalities (topical treatment, phototherapy, classic systemic therapy or BioLogicals) over a period of 12 months. To this end, a retrospective cost-of-illness study was conducted on 120 patients treated at the University Medical Centre Mannheim between 2005 and 2006. Inpatient therapy caused significantly higher direct medical, indirect and total annual costs than outpatient treatment (13,042 (sic) versus 2,984 (sic)). Its strong influence on cost levels was confirmed by regression analysis, with total costs rising by 104.3% in case of inpatient treatment. Patients receiving BioLogicals produced the overall highest costs, whereas outpatient treatment with classic systemic antipsoriatic medications was less cost-intense than other alternatives.
KW  - plaque-type psoriasis
KW  - health-care costs
KW  - patient preferences
KW  - disease severity
KW  - United States
KW  - moderate
KW  - life
KW  - multicenter
KW  - biologics
KW  - Germany
Y1  - 2013
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-128235
SN  - 1932-6203
VL  - 8
IS  - 10
ER  -